Fatigue - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 43

Fatigue - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Fatigue    Pipeline Review, Q4 2010”, provides an overview of the Fatigue    therapeutic pipeline. This report provides information on the therapeutic development for Fatigue   , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fatigue   . “Fatigue   -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Fatigue   .
- A review of the Fatigue    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fatigue    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- A snapshot of the global therapeutic scenario for Fatigue   .
- A review of the Fatigue    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fatigue    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fatigue Overview
Therapeutics Development
An Overview of Pipeline Products for Fatigue
Fatigue Therapeutics under Development by Companies
Fatigue Therapeutics under Investigation by Universities/Institutes
Companies Involved in Fatigue Therapeutics Development
Bristol-Myers Squibb Company
Sanofi-Aventis
Dainippon Sumitomo Pharma Co., Ltd.
MultiCell Technologies, Inc.
Chelsea Therapeutics, Inc.
PhytoHealth Corporation
Medice Arzneimittel Putter GmbH & Co. KG
Universities/Institutes Involved in Fatigue Therapeutics Development
Fatigue Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Methylphenidate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHN012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XRP6976 + Modafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Armodafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Armodafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Armodafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enbrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epoetin Alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epoetin Alfa + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Melatonin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Testosterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fatigue - Featured News
Dec 14, 2010: Hemispherx Receives FDA Extension For Pending NDA Of Chronic Fatigue Syndrome Treatment
Nov 29, 2010: Hemispherx Requests FDA For Extension Of Time For Ampligen NDA Submission
Nov 22, 2010: Hemispherx Announces Publication Of New Data On Ampligen’s Activity In Chronic Fatigue Syndrome In Journal Of Applied Research
Aug 19, 2010: Chelsea Initiates Investigator-Led Phase II Study Of Droxidopa In Chronic Fatigue Syndrome
Jun 14, 2010: MultiCell Retains CDSS To Manage MCT-125 Phase IIb Clinical Trial For PMSF In UK
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013